NPS Pharmaceuticals, Inc.

	Nasdaq: NPSP	Change symbol:

NEWS FROM THE WIRES NPS Pharmaceuticals reports steeper Q2 loss Aug 07 2001 02:49 PM PDT > More WIRE STORIES about this company  PROFILE NPS Pharmaceuticals' calcium receptor technology is the launching point for its research and development of treatments for hyperparathyroidism (HPT), osteoporosis, and epilepsy and other central nervous system (CNS) disorders. The company has research collaborations with such entities as Amgen, GlaxoSmithKline, and the pharmaceutical unit of Kirin Brewery. AMG-073, its lead HPT drug candidate, is in late-phase clinical trials in the US and Japan. NPS Pharmaceuticals and its partners are also applying the technology to discover an osteoporosis drug and treatments for dementia, schizophrenia, bipolar disorder, and other CNS conditions.  COMPETITION Bone Care International, Inc. (BCII) Eli Lilly and Company (LLY) GelTex Pharmaceuticals, Inc. (dossier)		STOCK ANALYSIS  View by:  Day   Day   Month   Month   Year   Year  FURTHER ANALYSIS • Advanced Charting • Deals  FINANCIAL OVERVIEW Fiscal Year-End: December 2000 Sales (mil.): 7,60 1-Yr. Sales Growth: 123.5% Employees: 136 Revenue per employee: $55,882,35  KEY PEOPLE • Hunter Jackson     CEO • Robert K. Merrell     CFO  CONTACT INFO 420 Chipeta Way Salt Lake City , UT 84108 US Phone: 801-583-4939 Fax: 801-583-4961 Online: Web Site

	Company Data   News, quotes & more

		Hoover's Company Capsule Copyright © 2001, Hoover's Inc. Austin, Texas. For changes and updates, contact Hoover's directly.